Mounjaro vs Zepbound: Which Is Right for You?
A detailed side-by-side comparison of Mounjaro and Zepbound, including cost, side effects, dosing, and provider availability.
At a Glance
Mounjaro
FDA ApprovedZepbound
FDA ApprovedDetailed Comparison
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active Ingredient | tirzepatide | tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA Approved | Yes | Yes |
| FDA Indication | Type 2 Diabetes (off-label for weight loss) | Chronic weight management |
| Dosing Schedule | Once weekly | Once weekly |
| Administration | Subcutaneous injection (pen) | Subcutaneous injection (pen) |
| Starting Price (lowest provider) | N/A | N/A |
| Provider Count | 15 | 16 |
| Insurance Coverage | 10 providers | 10 providers |
| Weight Loss Data | In the SURMOUNT-1 trial, patients on the highest dose of tirzepatide (15mg) lost an average of 22.5% of body weight over 72 weeks - the highest weight... | In the SURMOUNT-1 trial, Zepbound at the 15mg dose helped patients lose an average of 22.5% of body weight (about 52 lbs for a 230 lb person) over 72 ... |
How They Compare
Mounjaro and Zepbound both contain tirzepatide and work through the same GLP-1 receptor agonist mechanism. The primary differences are in their FDA indications and dosing. Mounjaro is indicated for type 2 diabetes (off-label for weight loss), while Zepbound is indicated for chronic weight management. Both are manufactured by Eli Lilly and have demonstrated significant clinical results in weight management.
Side Effects Comparison
Mounjaro
Common
- Nausea (most common during dose escalation)
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Indigestion
- Abdominal pain
Serious (Rare)
- Pancreatitis
- Gallbladder problems
- Hypoglycemia (especially with insulin)
- Kidney problems
- Allergic reactions
- Thyroid C-cell tumors (boxed warning, animal studies)
Zepbound
Common
- Nausea (up to 33%)
- Diarrhea (up to 25%)
- Vomiting
- Constipation
- Abdominal pain
- Injection site reactions
- Hair loss (reported in some patients)
Serious (Rare)
- Pancreatitis
- Gallbladder disease
- Kidney problems
- Severe allergic reactions
- Thyroid C-cell tumors (boxed warning)
- Depression or suicidal thoughts (under investigation)
Dosing Schedule Comparison
Mounjaro
Subcutaneous injection (pen) - Once weekly
Zepbound
Subcutaneous injection (pen) - Once weekly
Frequently Asked Questions
What is the difference between Mounjaro and Zepbound?
Mounjaro (Tirzepatide) is made by Eli Lilly and is FDA-approved. Zepbound (Tirzepatide) is made by Eli Lilly and is FDA-approved. Both contain the same active ingredient (tirzepatide) but differ in manufacturing, dosing, and FDA indication.
Which is more affordable, Mounjaro or Zepbound?
Based on available providers, Mounjaro starts at $0/month while Zepbound starts at $0/month. Both have similar starting prices. Actual costs depend on your provider, insurance coverage, and dose level.
Which is more effective for weight loss, Mounjaro or Zepbound?
Both medications have shown significant weight loss results. Clinical trials suggest tirzepatide (dual GIP/GLP-1 agonist) may produce slightly greater average weight loss than semaglutide (GLP-1 agonist alone), though individual results vary significantly. Your healthcare provider can help determine which is best for your specific situation.
Can I switch from Mounjaro to Zepbound?
Switching between GLP-1 medications is possible but should always be done under medical supervision. Your provider will determine the appropriate starting dose for the new medication and may adjust the transition schedule based on your current dose and response. Since both contain the same active ingredient, the transition may be more straightforward.
Related Comparisons
Medical Disclaimer: This comparison is for educational purposes only and should not replace professional medical advice. Individual results vary. Always consult your healthcare provider before starting or changing any medication.